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LP-BM5, a retroviral isolate, induces a disease featuring an acquired immunodeficiency syndrome termed murine AIDS (MAIDS). Many of
the features of the LP-BM5-initiated disease are shared with HIV/AIDS. Our lab has shown that the interaction of B and CD4 T cells that is central
to MAIDS pathogenesis requires ligation of CD40 on B cells by CD154 on CD4 T cells. Despite this strict requirement for CD154 expression,
whether CD4 T cell receptor (TCR) occupancy is essential for the induction of MAIDS is unknown. To block TCR engagement, Tg mouse strains
with monoclonal TCR of irrelevant peptide/MHC specificities, all on MAIDS-susceptible genetic backgrounds, were tested: the study of a panel of
TCR Tg CD4 T cells controlled for the possibility of serendipitous crossreactive recognition of virus-associated or induced-self peptide, or
superantigen, MHC complexes by a given TCR. The results argue that TCR engagement is not necessary for the induction of MAIDS.
© 2006 Elsevier Inc. All rights reserved.Keywords: Murine AIDS (MAIDS); LP-BM5 retrovirus; Pathogenesis; Immunodeficiency; CD4 T cells; CD154; CD40; T cell receptor (TCR); Signal 1; Transgenic
(Tg)Introduction
CD40 ligand (CD40L or CD154) is a 33-kDa transmem-
brane glycoprotein that is transiently expressed on the surface of
activated T cells, predominantly CD4 T cells. Its receptor,
CD40, is found on B cells, dendritic cells, monocytes, and some
other cell types. The CD154/CD40 system is crucially involved
in immunity because cognate interactions between CD154 and
CD40 generate intra- (through CD40) and inter-cellular signals
that result in up-regulation of a variety of cell surface and
soluble molecules that ultimately impact humoral and cellular
immunity, as well as inflammation and other disease processes
(e.g. Laman et al., 1996; Danese et al., 2006). For example,
CD154 and CD40 are overexpressed in both forms of
inflammatory bowel disease (IBD) (Liu et al., 1999; Danese⁎ Corresponding author. Department of Microbiology and Immunology,
Dartmouth Medical School, 603W Borwell Research Building, One Medical
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doi:10.1016/j.virol.2006.10.002et al., 2006), Crohn's disease (CD) (Battaglia et al., 1999), and
ulcerative colitis (Polese et al., 2002). These studies and others
strongly indicate that the CD154/CD40 pathway plays a key
pathogenic role in intestinal inflammation. A number of studies
have focused on the impact of CD154/CD40 interactions on the
immunopathogenesis of other autoimmune diseases, such as
systemic lupus erythematosus (SLE) (Desai-Mehta et al., 1996;
Koshy et al., 1996), rheumatoid arthritis (RA) (MacDonald et
al., 1997), multiple sclerosis (Gerritse et al., 1996), and Graves'
disease (Faure et al., 1997); as well as on allograft rejection
(Reul et al., 1997).
The interaction of CD154 and CD40 is not restricted to the
regulation of immune responses and dysfunction resulting in
autoimmunity, but also often plays an important role in the
development of effector cells that function at local sites of
infection and inflammation (Reichmann et al., 2000). In vivo
studies have indicated the important role of CD40 ligation by
CD154 in thymus-dependent humoral immune responses and
germinal center formation (Allen et al., 1993; Xu et al., 1994;
Liu et al., 1999). CD154 also is a critical molecular player in
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antigen-specific CD4 T cells lacking CD154 failed to expand
upon antigen challenge of the recipients, showing that
expression of CD154 is required for in vivo priming of CD4
T cells and therefore for the initiation of specific T-cell immune
responses (Grewal et al., 1995). Similarly, CD154−/− mice
display a deficiency in T cell-dependent macrophage-mediated
immune responses (Stout et al., 1996). Thus, CD154 ligation of
CD40 is important in the protective cell-mediated immune
responses conferred by T cell-directed activated macrophage
effector function against intracellular parasite infections such as
Pneumocystis, Listeria monocytogenes, Leishmania (Grewal et
al., 1997; Soong et al., 1996; Campbell et al., 1996), and a T.
gondii-driven experimental model of acute ileitis (Li et al.,
2002). CD154/CD40 interactions are also required for the
priming and expansion of antigen-specific CD4 T cells and in
the induction of co-stimulatory activity on antigen-presenting
cells (APCs) (Grewal et al., 1997). CD154/CD40 binding and
signaling are also well documented to have a key role in APC
maturation and survival in the induction of adaptive immune
responses, particularly the activation of naïve T cells by
dendritic cells (Grewal et al., 1997; Caux et al., 1994; Peguet-
Navarro et al., 1995; Cella et al., 1996).
The LP-BM5 retroviral isolate consists of a pathogenic
defective murine retrovirus (BM5def) that requires replication-
competent ecotropic helper viruses (e.g. BM5eco) for its entry
into cells and spread in vivo. The ensuing murine acquired
immunodeficiency syndrome, termed murine AIDS (MAIDS)
(Latarjet and Duplan, 1962; Mosier et al., 1985), exhibits
many features shared with HIV-induced disease in man (Aziz
et al., 1989; Jolicoeur, 1991; Morse et al., 1992; Tayar et al.,
1999; Casabianca et al., 2003). Similarities include early onset
hypergammaglobulinemia (hyper-Ig), splenomegaly, and lym-
phadenopathy; dependence on CD4 T cells for initiation of
disease; loss of CD4 T cell function; severely depressed T and
B cell responses; increased susceptibility to infection and
death when exposed to normally nonpathogenic microorgan-
isms; and the development of terminal B-cell lymphomas.
Although there are also differences between MAIDS and
human AIDS, the study of MAIDS, as the most commonly
used murine system of retrovirus-induced immunodeficiency,
offers many advantages. Thus, the availability of informative
inbred, Tg, knockout, and other mouse strains, and ability to
do in vivo pathogenesis experiments allows direct investiga-
tion of the cellular and molecular mechanisms required for the
development of retroviral pathogenesis, including the asso-
ciated immunodeficiency.
Both CD4 T cells and B cells are required for disease
induction and progression. Severe combined immunodeficient
(SCID) mice (lacking mature T and B cells) do not develop
MAIDS (Simard et al., 1997). B6 mice that were depleted of B
cells from birth by chronic administration of rabbit anti-mouse
IgM antibodies (μ-suppressed) are resistant to LP-BM5
MAIDS (Cerny et al., 1990). It has been reported that the
main targets of initial LP-BM5 retrovirus infection are B cells
(Kim et al., 1994; K. Green, unpublished data), and to some
extent macrophages (Cheung et al., 1991) and T cells (Kim etal., 1994; K. Green, unpublished data). However, B-cell
infection by itself is not progressive and does not lead to
disease in the absence of mature CD4 T cells (Klinman and
Morse, 1989; Cerny et al., 1990). Indeed, an early hyperactivity
of CD4 T cells may contribute to the pathogenesis of MAIDS
(Mosier et al., 1987; Yetter et al., 1988). Thus, in vivo
depletion of CD4 T cells by treatment with the anti-CD4-
specific mAb GK1.5, before LP-BM5 infection rendered
susceptible B6 mice resistant to the development of MAIDS
(Yetter et al., 1988). Similarly, congenitally-athymic nude B6
mice become infected but do not develop significant LP-BM5
induced MAIDS (Mosier et al., 1987). However, if recon-
stituted with CD4 T cells from B6 donor mice, B6.nude
recipients develop MAIDS upon LP-BM5 infection (Yetter et
al., 1988; Giese et al., 1994). In contrast, by comparing the
adoptive transfer of T cell subsets into B6.nude mice, it was
demonstrated that CD8 T cells are not required for LP-BM5
induced pathogenesis (Green et al., 2001).
These and other results suggested that an interaction
between B and CD4 T cells is critical for the pathogenesis of
MAIDS. Thus, in additional adoptive transfer experiments, our
lab showed that if B6.nude recipients were reconstituted with
CD154+/+, but not CD154−/−, CD4 T cells, they converted to
disease susceptibility (Green et al., 2001). Reciprocally, with
regard to the cell type interacting with CD154+ CD4 T cells,
B6 CD40−/− mice, which are resistant to LP-BM5-induced
MAIDS (Green et al., 2001; Yu et al., 1999), became
susceptible to LP-BM5-induced disease after reconstitution
with highly purified wild-type (w.t.) (CD40+) B cells, but not
after receiving purified wild-type dendritic cells (DC) or a
combined CD40+ population composed of DC and macro-
phages obtained from B6.SCID mouse donors (Green et al.,
2001). Indeed, by F2 genetic crossing and screening to
generate a B6.CD40−/− SCID recipient, combined transfer of
only w.t. (CD154+) CD4 T cells and w.t. (CD40+) B cells
allowed for LP-BM5 infection to cause MAIDS (K. Green,
unpublished data). In a follow-up study, we demonstrated that
B6 mice deficient for both the CD80/CD86 (B7.1/B7.2) co-
stimulatory ligands are susceptible to LP-BM5 induction of
MAIDS (Green et al., 2002). These results on the APC (B cell)
expressed B7 ligands, coupled with data from another
laboratory on the CD80/CD86 receptor-CD4 T cell expressed
CD28 (Morawetz et al., 1998), suggested that CD28/CD80-
CD86 interactions are not absolutely required for the initiation
of MAIDS or the commitment to disease progression.
Although the classic upregulation of CD80/CD86 after CD40
ligation is thus not necessary, we have used a panel of chimeric
CD40 Tg mice on the CD40−/− background to confirm that
CD40 signaling is needed for MAIDS induction and is
differentially mediated by TRAF binding to the TRAF 6 site
(vs the TRAF 2/3/5 site) on the CD40 cytoplasmic tail (Green
et al., 2004). Collectively, these findings provide clear
evidence that activated CD4 T cell CD154 ligation of B cell
CD40 and downstream signaling events are required for
MAIDS (Green et al., 2001, 2004).
In view of the absolute requirement for CD154 expression, it
is not clear, however, whether there is a role for CD4 T cell
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MHC complexes in the induction of MAIDS. It is well accepted
that, in general, the induction of CD154 depends on TCR
occupancy and Signal 1 in the T cell activation paradigm. But it
is unknown if ligation of the TCR expressed by the required CD4
T cells is necessary for MAIDS pathogenesis. If TCR is indeed
engaged, then it would follow that a viral peptide, induced self
peptide, or superantigen (SAg) complexed with MHC class II
would be the TCR ligand driving Signal 1 propagation.
However, as no LP-BM5 virus-encoded or -associated peptide,
or SAg, has yet been defined that could provide the ligand for the
CD4 TCR in the context of MAIDS (Hugin et al., 1991;
Muralidhar et al., 1992; Gilmore et al., 1993; McCarty et al.,
1996; Doyon et al., 1996; Hayashi and Kanagawa, 1999), the
question of a requirement for CD4 TCR engagement in MAIDS
can not be approached using antibody or other reagents to block
the ligation of the TCR by these putative peptide or SAg–MHC
complexes. Also, it is not possible to study the need for the TCR
by use of TCR−/−mice because the required CD4 Tcells will not
be present. Thus, this key question of the role, if any, of the CD4
TCR is addressed here by utilizing a panel of CD4 T cells that
express class II-restricted transgenic (Tg) TCR that are specific
for different peptides totally unrelated to LP-BM5 virus, and are
of various Vβ chain compositions. To determine the ability of
these CD4 T cells to support LP-BM5 induction of MAIDS in
the absence of classic TCR ligation, it is crucial that only TCRTg
CD4 T cells are present. To this end, one or both of two
approaches were utilized. First, highly purified TCR Tg CD4 T
cells were separated and adoptively transferred into either B6.
nude or B6.TCRα−/− recipients, that have no pre-existing CD4 T
cell compartment. Second and alternatively, to avoid the
presence of non-Tg CD4 T cells, these TCR Tg strains were
backcrossed onto the B6.TCRα−/− or B6.RAG-1−/− background
and infected directly.
Results and discussion
Adoptive transfer of polyclonal CD4 T cells converts MAIDS
resistant B6.nude recipients to a MAIDS susceptible phenotype
To set up the adoptive transfer system, in initial experiments
CD4 T cells were obtained by either positive or negative
selection methods of purifying mature splenic CD4 T cells from
normal donor C57BL/6 mice. After adoptive transfer of such
purified CD4 T cells into B6.nude recipients, a portion of the
recipients was infected i.p. with LP-BM5 virus 48 h after
reconstitution, while the others served as non-infected control
groups. Progression to MAIDS was evaluated 8 to 12.5 weeks
later by the following standard readouts of MAIDS-associated
symptoms, which we and others have previously established
(Mosier et al., 1987; Klinman and Morse, 1989; Morse et al.,
1992; Green et al., 1996, 1998, 2001, 2002, 2004): (i) spleen
size, with enlargement indicating MAIDS-associated B- and T-
cell lymphoproliferation; (ii) serum IgG2a and IgM levels, with
increases due to MAIDS polyclonal B-cell activation; and (iii)
splenic B-cell responses to lipopolysaccharide (LPS) stimula-
tion, with decreases indicative of B-cell-associated MAIDS-induced immunodeficiency. For all the experiments, the early
activational MAIDS disease parameter, hypergammaglobuline-
mia (serum IgM and IgG2a levels), was also assessed at 7 to
8 weeks post infection (p.i.) by analysis of serum taken without
sacrifice of the mouse. We have previously shown that the
adoptive transfer of CD4 T cells converted B6.nude mice to
MAIDS susceptibility (Green et al., 2001; Li and Green, 2006).
Comparing positive selection and negative selection approaches
used to purify the CD4 T cells, there were no substantial
differences in the pattern of the results obtained, which were
also roughly comparable to those observed in intact B6 mice (Li
and Green, 2006).
The MAIDS susceptibility of B6.nude vs B6.TCRα−/− recipients
reconstituted with polyclonal CD4 T cells appears to be
equivalent
Like B6.nude mice, B6.TCRα−/− mice are also resistant to
LP-BM5 induced disease due to lack of the required CD4 T
cells. Here, we compared head to head B6.nude recipients and
B6.TCRα−/− recipients reconstituted with total polyclonal CD4
T cells purified from B6 donors. Upon LP-BM5 virus infection,
these two recipient groups developed essentially the same
amount ofMAIDS, with all the disease parameters in agreement;
here for the sake of brevity, we show only one activational
parameter: spleen weight (Fig. 1A), and an immunodeficiency
parameter: splenic mitogen response to LPS (Fig. 1B). Thus, B6.
nude and B6.TCRα−/− mice can be used interchangeably as
recipients of CD4 T cell adoptive transfer.
Adoptive transfer of OT-II TCR Tg+ CD4 T cells converts
B6.nude recipients to susceptibility to MAIDS pathogenesis
To determine whether CD4 T cells of monoclonal specificity
could mediate LP-BM5 induced MAIDS, we first studied OT-II
TCR Tg mice, whose CD4 T cells are specific for the irrelevant
antigen ovalbumin, as presented by MHC class II (I-Ab) (Table
1). By flow cytometric analysis of OT-II TCR Tg mice, we
found that only ∼73% of splenic CD4 T cells were actually
TCR Tg+ (Fig. 2A, upper right). It was important to avoid the
remaining ∼27% CD4 T cells that express non-Tg TCR chains,
because it may well be that these cells would satisfy the CD4 T-
cell requirement for MAIDS induction. Thus, our first approach
was to purify OT-II TCRVβ5.1, 5.2 Tg+ CD4 T cells by use of
the corresponding anti-Vβ mAb and Miltenyi bead selection
(see Materials and methods) prior to their adoptive transfer. In
this way highly purified (≥98%) TCR Tg positive CD4 T cells
(Fig. 2A, lower right), vs purified polyclonal B6 CD4 T cells
(Fig. 2A, lower left) from B6 donors (Fig. 2A, upper left) as a
control, were transferred into B6.nude recipients. Following
LP-BM5 infection 48 h after adoptive transfer, induction of
MAIDS was subsequently determined by assessing the standard
panel of disease-related parameters. However, for the sake of
brevity, here we only show one activational parameter: spleen
weight (Fig. 2B), and an immunodeficiency readout: mitogen
response to LPS (Fig. 2C). All the other disease parameters
agreed (data not shown) in that: the B6.nude recipients
Fig. 2. Purified OT-II TCR Tg+ CD4 T cells mediate MAIDS. CD4 T cells (A,
lower left) purified from B6 donors (A, upper left), or OT-II TCR Tg+ CD4 T
cells (A, lower right) purified from OT-II TCR Tg donors (A, upper right) were
adoptively transferred into B6.nude recipients. Mice were assayed for disease at
9 weeks p.i. with LP-BM5. Here, one activational parameter: spleen weight (B),
and one immunodeficiency parameter: splenic mitogenic response to LPS (C),
Fig. 1. Both B6.nude and B6.TCRα−/− recipients equally supported MAIDS.
CD4 T cells purified from B6 donors were adoptively transferred into either B6.
nude or B6.TCRα−/− recipients. After LP-BM5 inoculation, disease was
assessed in infected or control mice at 10 weeks p.i. by the standard MAIDS
readout panel. Shown here are one representative activational parameter: spleen
weight (A) and one immunodeficiency parameter: splenic mitogenic response to
LPS (B), compared to uninfected control mice, with all other parameters also
demonstrating that B6.nude and B6.TCRα−/− recipients reconstituted with B6
CD4 T cells are equivalently MAIDS susceptible. The results were significant
(*P<0.05) or not significant (NS, P≥0.05). The data shown are representative
of a total of three experiments, with the same pattern of results always obtained.
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significant MAIDS, compared to their non-infected control
group (Figs. 2B, C) or infected B6.nude mice not receiving CD4
T-cell transfer (data not shown). However, significantly less
disease was observed with OT-II TCR Tg CD4 transfer,
compared to the infected recipients previously reconstituted
with total polyclonal CD4 T cells purified from normal B6
donors (Figs. 2B, C).Table 1
A panel of TCR-transgenic strains to address the role of the TCR
Tg TCR
mouse strain
Background
strain
MHC
restriction
Foreign peptide
specificity
TCRVα/Vβ
subunits
OT-II B6 I-Ab Ovalbumin:
OVA323–339
Vα2/Vβ5.1,5.2
TEa B6 I-Ab Eα52–68,
class II I-Eα
d -chain
Vα2/Vβ6
ANDb/b B6 I-Ab Pigeon cytochrome
C: PCC81–104
Vα11/Vβ3
ANDk/k B10.BR I-Ek Pigeon cytochrome
C: PCC81–104
Vα11/Vβ3
are depicted; with all other parameters consistent in demonstrating that B6.nude
recipients reconstituted with OT-II TCRTg+ CD4 T cells mediated MAIDS. The
results were significant (*P<0.05) or not significant (NS, P≥0.05). This
experiment has been done a total of three times, with the same pattern of results
always obtained.OT-II TCR Tg TCRα−/− mice: susceptibility to
LP-BM5-induced MAIDS and the effect of OVA immunization
Alternatively to eliminate non-TCR-Tg CD4 T cells, we
crossed these OT-II TCR Tg mice onto a B6.TCRα−/−
background, and screened the offspring by flow cytometry to
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endogenous TCRα−/− status (Fig. 3B). We thus obtained OT-II
TCR Tg+ TCRα−/− mice, whose CD4 T-cell compartment
consisted of essentially 100% TCR Tg cells, and directly
infected these mice, vs w.t. B6 controls, with LP-BM5 virus.
Similar to the results obtained by the adoptive transfer approach
(Figs. 2B, C), again, there was clear evidence that OT-II TCRTg
CD4 T cells mediated substantial LP-BM5-induced MAIDS—
here as depicted by one activational parameter: hyper IgG2a
levels (Fig. 3C), and one immunodeficiency parameter: the
splenic mitogenic response to LPS (Fig. 3D).
Thus, OT-II TCR Tg CD4 T cells, when studied in isolation
from non-Tg CD4 T cells, do mediate LP-BM5 induced
MAIDS, as determined by both the adoptive transfer and
TCRα−/− backcross approaches. Therefore, given the absence
of the OVA protein antigen source of the corresponding peptideFig. 3. The OT-II TCR Tg strain on the B6.TCRα−/− background is MAIDS suscep
(see Materials and methods). The offspring were screened for Tg positivity (A) by u
TCRα−/− status (B) by PCR. Experimental mice that were both Tg positive and als
BM5. Disease was assessed at 10 weeks p.i. by the standard MAIDS readout panel. S
and one immunodeficiency parameter: splenic mitogenic response to LPS (D), w
MAIDS susceptible. The results were significant (*P<0.05) or not significant (NS, P
of results always obtained.epitope, TCR occupancy by peptide/MHC seems to not be
absolutely required for induction of MAIDS by LP-BM5
infection. However, in view of the partial disease observed, it
seemed possible that if we provided the cognate OVA peptide
for TCR ligation and Signal 1 by injecting OVA in vivo, this
strategy might lead to more profound disease. Thus, OT-II TCR
Tg TCRα−/− mice received multiple doses of OVA plus
adjuvant immunization prior to, and subsequent to, LP-BM5
infection (see Materials and methods).
To make sure that the OVA delivered was sufficient to
have activated the OT-II TCR Tg cells in vivo and provided
TCR Signal 1, peripheral blood lymphocyte samples were
obtained at several time points p.i. These CD4 TCR Tg cells
were specifically analyzed by flow cytometry via staining for
the activational markers CD62L and CD69; and functional
assessment of their ability to proliferate in vitro in response totible. The OT-II TCR Tg strain was crossed onto the B6.TCRα−/− background
se of FITC anti-TCRVβ5.1, 5.2, and PE anti-CD4 mAbs; and also screened for
o on a TCRα−/− background, versus B6 control mice, were infected with LP-
hown here are one representative activational parameter: hyper IgG2a level (C)
ith all other parameters demonstrating that OT-II TCR Tg TCRα−/− mice are
≥0.05). This experiment was done a total of three times, with the same pattern
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that immunizing with OVA in vivo provided clear evidence
for activation specifically of OT-II TCR Tg CD4 T cells at
days 2, 5, and 14 p.i.: e.g. at day 14 p.i., there was a two-fold
decrease of CD62L expression and a three-fold increase in
CD69 expression among the TCR Tg CD4 T cells from the
OT-II TCR Tg+ TCRα−/− mice that were immunized with
OVA and infected by LP-BM5 virus versus mice that were
only infected. In addition, a strong OVA-dependent in vitro
recall proliferative response was observed at several time
points at days 2, 5 and 14, p.i. (data not shown). In this
context of documented TCR-mediated activation and pre-
sumed Signal 1 generation, the development of LP-BM5-
induced MAIDS was subsequently assessed as shown here by
one activational parameter: spleen weight (Fig. 4A), and an
immunodeficiency parameter: the mitogen response to LPS
(Fig. 4B). In agreement with the other disease parameters not
shown, and the results of Figs. 3A and B above, OT-II TCR
Tg CD4 T cells mediated clear MAIDS. However, there was
no evidence supporting an increased degree of MAIDS by
OVA immunization in vivo.Fig. 4. In vivo activation of TCR Tg CD4 T cells with cognate antigen did not
enhance the degree of LP-BM5 retrovirus-induced MAIDS. OT-II TCR Tg+
TCRα−/− mice received multiple doses of OVA protein antigen in vivo (see
Materials and methods). Disease was assessed at 8.5 weeks p.i., with one
activational parameter (spleen weight) (A), and one immunodeficiency
parameter (splenic mitogenic response to LPS) (B) depicted as representative
of all other disease read-outs, which showed the same pattern of results. The
results were significant (*P<0.05) or not significant (NS, P≥0.05). This
experiment has been done twice; the same pattern of result was always obtained.Other I-Ab restricted TCR Tg strains and the ability of their
CD4 T cells to mediate MAIDS
Despite our repeatable results obtained from the OT-II TCR
Tg mice, it was important to study additional TCR Tg strains.
First, although the specificity of the Tg OT-II TCR for OVA, as
an irrelevant antigen, would appear to eliminate TCR ligation,
signaling through the TCR could have occurred due to a random
cross-reactive recognition of a virus-encoded, or -induced self,
peptide. If more than one irrelevant TCRTg strain mediated LP-
BM5-induced MAIDS, the possibility that this was dependent
on another crossreactive stimulation of the TCR seemed
unlikely. Second, considering differing Vβ and Vα TCR subunit
compositions, multiple TCR Tg strains needed to be assessed to
test the possibility that the TCR might be ligated by a virus-
encoded, or -induced-self superantigen (SAg). Third, the
observation that OT-II TCR Tg CD4 T cells mediated MAIDS,
but only to a partial extent compared to polyclonal CD4
T cells, begged the question as to whether all TCR Tg CD4 T
cells were capable, but limited, in their ability to supportMAIDS
pathogenesis.
To address these questions, the ANDb/b TCRTg (specific for
PCC81–104) and TEa TCR Tg (specific for Eα52–68) strains
(Table 1) were studied in parallel. Both the ANDb/b and TEa
TCR Tg strains were crossed onto the B6.RAG-1−/− back-
ground (see Materials and methods) to eliminate/limit the
presence of non-Tg CD4 T cells (Figs. 5A, B). As RAG-1−/−
background mice are also deficient in the B-cell compartment
that is necessary for MAIDS development (Cerny et al., 1990),
polyclonal CD19 B cells purified from w.t. B6 donors (see
Materials and methods) were adoptively transferred into the
ANDb/b TCR Tg+ RAG-1−/− (Fig. 5A, left panel) and TEa TCR
Tg+ RAG-1−/− recipient mice (Fig. 5B, left panel) as the
experimental groups. As positive controls for this transfer,
aliquots of the same purified CD19 B cells (plus polyclonal
CD4 T cells) from B6 donors were adoptively transferred in
parallel into either ANDb/b TCR Tg− RAG-1−/− (Fig. 5A, right
panel) or TEa TCR Tg− RAG-1−/− (Fig. 5B, right panel)
littermate TCRTg negative recipients. Again, showing only one
of the standard panel of activational parameters: spleen weight
(Fig. 5C) and an immunodeficiency parameter: mitogen
response to LPS (Fig. 5D) for brevity, the results were clear
and contrasting. ANDb/b TCR Tg+ RAG-1−/− mice reconsti-
tuted with CD19 B cells clearly developed LP-BM5-induced
MAIDS, with a roughly similar degree of penetrance relative to
the non-Tg recipient controls that received polyclonal B6 CD4
T cells and B cells. Despite thus proving that the quality and
quantity of B6 CD19 B cells transferred was sufficient for
disease induction, in sharp contrast the TEa TCRTg+ RAG-1−/−
B-cell reconstituted mice did not develop significant MAIDS,
compared to their non-infected control group, for either the
activational or immunosuppressive disease parameters (Figs.
5C, D, and data not shown). These results were highly
reproducible: ANDb/b TCR Tg mice were MAIDS susceptible
in 4/4 experiments of this type, and the same conclusion was
reached both by infection of the intact original Tg strain, and via
adoptive transfer of ANDb/b TCR Tg CD4 T cells into B6.
Fig. 5. The ANDb/b TCR Tg strain, but not the TEa TCRTg strain, crossed onto a B6.RAG-1−/− background is MAIDS susceptible. The offspring from ANDb/b TCR
Tg and TEa TCR Tg strains crossed onto a B6.RAG-1−/− background were screened for Tg positivity (A and B) by use of FITC anti-TCRVβ6 (A) or Vβ3 (B),
respectively; PE anti-CD19; and APC anti-CD4. The experimental Tg+ mice on the RAG-1−/− background (A and B, left panel) were recipients of adoptive transfer of
CD19 B cells, while the control Tg− mice on the RAG-1−/− background (A and B, right panel) received both CD4 T and CD19 B cells (see Materials and methods).
Disease parameters were assayed at 12.5 weeks p.i. by the standard MAIDS readout panel. Shown here are one representative activational parameter: spleen weight
(C), and one immunodeficiency parameter: splenic mitogenic response to LPS (D), with all other parameters clearly demonstrating that ANDb/b TCR Tg RAG-1−/−
mice are MAIDS susceptible but TEa TCR Tg RAG-1−/− mice are MAIDS resistant. The results were significant (*P<0.05) or not significant (NS, P≥0.05). This
experiment has been performed a total of four times, with the same pattern of results always obtained.
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Tg mice failed to develop LP-BM5-induced MAIDS (Figs. 5C,
D) in a total of four experiments.
Evidence against superantigen involvement in MAIDS
pathogenesis
The observations that the OT-II and ANDb/b TCR Tg strains
were MAIDS susceptible, but not the TEa TCR Tg strain, could
be interpreted to suggest that a SAg, binding to Vβ5.1, 5.2 and
Vβ3, but not Vβ6 (Table 1), selectively ligated these Tg TCR
and thus was critically involved in MAIDS pathogenesis. To
approach the possibility of SAg involvement as the basis for the
differential ability of TCR Tg CD4 T cells to mediate MAIDS,
an additional highly related TCR Tg strain, was studied in
parallel to the ANDb/b TCR Tg strain just shown to be MAIDS
susceptible. Thus, the AND TCR Tg has also been bred onto,
and thus selected on, the H-2k/B10.BR background. Impor-
tantly, CD4 T cells of the ANDb/b and ANDk/k TCR Tg strains,
are specific for the same peptide of the MAIDS-irrelevant
antigen pigeon cytochrome C: PCC81–104, and express the same
TCR subunits. Thus, as long as the putative SAg is presented byboth MHC class II I-Ab and I-Ak/I-Ek molecules, the ANDk/k
TCR Tg strain should be MAIDS susceptible as is the ANDb/b
TCR Tg strain (Figs. 5C, D).
After LP-BM5 infection, these two TCRTg strains, and their
respective B6 and B10.BR background control strains, were
assessed for MAIDS development by the standard disease
parameter panel. Depicting data representative of all disease
parameters, shown here are one activational parameter: spleen
weight (Fig. 6A), and one immunodeficiency read-out: mitogen
response to LPS (Fig. 6B). ANDb/b TCR Tg mice were MAIDS
susceptible as expected; in fact, their extent of MAIDS
splenomegaly (and hyper-Ig/data not shown) was, if anything,
more pronounced compared to their B6 background control
mice. However, clearly, there was no evidence that ANDk/k
TCR Tg mice developed any MAIDS symptoms, considering
all disease parameters at 10 weeks p.i. Given that the control for
the ANDk/k background, the B10.BR strain, displayed sig-
nificant MAIDS symptomatology upon LP-BM5 infection,
importantly it could be inferred that any SAg necessarily
involved could be presented by H-2k class II MHC. Thus, the
lack of disease in infected ANDk/k TCRTg mice was not simply
due to the consequences of the selection of this Tg TCR on the
Fig. 6. The ANDb/b TCR Tg strain is MAIDS susceptible, while the ANDk/k
TCR Tg strain is not. ANDb/b TCR Tg and ANDk/k TCR Tg mice, plus their
respective B6 and B10.BR control groups, were infected with LP-BM5 and
studied in parallel. Disease parameters were assayed 10 weeks p.i., and shown
here are one activational parameter: spleen weight (A), and one immunodefi-
ciency parameter: mitogen response to LPS (B), with all other parameters clearly
demonstrating that B6, ANDb/b TCR Tg, and B10.BR mice are MAIDS
susceptible but ANDk/k TCR Tg mice are MAIDS resistant. The results were
significant (*P<0.05) or not significant (NS, P≥0.05). This experiment has
been performed a total of three times, with the same pattern of results
consistently obtained.
Fig. 7. The difference in MAIDS susceptibility mediated by TCR Tg+ CD4 T
cells of the ANDb/b and ANDk/k TCR Tg strains as determined by parallel
adoptive transfer experiments. The ANDb/b and ANDk/k TCR Tg mice were
phenotyped for Tg status by using FITC anti-TCRVβ3 and PE-anti-CD4 mAbs
(A). Purified (≥98%) ANDb/b and ANDk/k TCR Tg+ CD4 T cells (2×107)
isolated from the respective TCR Tg donors, or control w. t. B6 and B10.BR
CD4 T cells, were adoptively transferred into B6.TCRα−/− recipients, followed
by LP-BM5 infection (2×105 PFU). Disease parameters were assayed
10.5 weeks p.i.; here shown are one representative activational parameter:
spleen weight (B), and one immunodeficiency parameter: splenic mitogenic
response to LPS (C), with all other MAIDS read-outs in agreement: only when
ANDk/k TCR Tg CD4 T cells were used to reconstitute B6.TCRα−/− recipients
was MAIDS development not observed. The results were significant (*P<0.05)
or not significant (NS, P≥0.05). This experiment has been performed twice,
with the same panel of result consistently obtained.
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and these results thus argued against TCR ligation by a SAg as a
requisite for MAIDS.
For two reasons it was important to follow up this direct
infection type of experiment with the adoptive transfer
approach. First, the B10.BR (H-2k) strain, which controlled
for the differential genetic background of the ANDk/k TCR Tg
strain, appeared to be somewhat less susceptible to MAIDS
induction than the B6 (H-2b) background strains, at least based
upon splenomegaly (Fig. 6A), although the immunodeficiency
parameter (Fig. 6B) suggested essentially full disease. This is in
keeping with previous reports that, with regard to MHC-control
of MAIDS susceptibility, H-2b is more permissive than H-2k
(Makino et al., 1990). Thus, if a MAIDS-associated SAg is
critical to disease pathogenesis, it may be less well presented by,
or recognized in association with, H-2k class II MHC than H-2b
class II. Second, the ANDb/b vs ANDk/k TCR Tg strains have
different levels of “contaminating” non-TCR Tg CD4 T cells
present, and this could account for the differential ability of the
ANDb/b, but not the ANDk/k, strain to develop LP-BM5-
induced MAIDS. Thus, by flow cytometric analysis there wason average only about 80% to 83% of total CD4 T cells in
ANDb/b TCR Tg mice that were actually Tg+ (Fig. 7A, left
panel), whereas there was an average of 90% to 93% of CD4 T
cells that were ANDk/k TCRTg+ (Fig. 7A, right panel). To make
sure that the disease induced in the ANDb/b, but not the ANDk/k,
Fig. 8. The resistance of the TEa and ANDk/k TCR Tg strains to MAIDS is not
due to insufficient viral infection, or a reduction in viral load. Expression of
the BM5def and BM5eco viruses was determined by separate real-time RT-
PCR assays with normalization to the expression of β-actin as we previously
published (Cook et al., 2003; Green et al., 2004). Shown here are the results of
the viral load for the mouse groups (A) of Fig. 5 and (B) of Figs. 6 and 7, with
all the non-infected groups' data pooled and presented together as “control”,
which exhibited no detectable (ND) viral load. The results were not
significantly (NS) different among all the infected groups of both (A) as
shown, and also (B), although here, for simplicity, only the most important
statistical comparisons of the infected ANDb/b versus ANDk/k groups are
shown.
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contaminating non-Tg CD4 T cells which could mediate
MAIDS, and to provide for a common MHC class II
presentation of the putative SAg, TCR Tg+ CD4 T cells were
purified from either ANDb/b, or ANDk/k, TCRTg donors (purity
≥98%, data not shown). These TCR Tg CD4 T cells were
adoptively transferred into B6.TCRα−/− recipients, followed by
LP-BM5 infection.
Here, we show one representative activational parameter:
spleen weight (Fig. 7B), and an immunodeficiency parameter:
the mitogen response to LPS (Fig. 7C). B6.TCRα−/− recipients
reconstituted with purified ANDb/b TCR Tg+ CD4 T cells again
mediated significant MAIDS as expected from the results of
Fig. 6. In sharp contrast, B6.TCRα−/− recipients reconstituted in
parallel with ANDk/k TCR Tg+ CD4 T cells failed to
demonstrate any signs of the disease, considering all tested
MAIDS parameters (Figs. 7B, C, and data not shown). To
control for the differences in genetic backgrounds in these
adoptive transfer experiments, we adoptively transferred
polyclonal CD4 T cells from either B6 or B10.BR donors into
B6.TCRα−/− recipients. The results clearly showed that CD4 T
cells of both control groups readily mediated substantial
MAIDS (Figs. 7B, C). Thus, the resistance to MAIDS observed
for the ANDk/k donor strain in these adoptive transfer
experiments (or when disease was assessed in the direct
infection experiments of this TCRTg strain, see Fig. 6), was not
due to the B10.BR background.
Lack of viral pathogenesis mediated by TEa and ANDk/k TCR
Tg strains does not correlate with reduced viral load
It was important to assess whether a differential ability to
become infected and/or to allow the spread of the component
viruses was the basis for the resistance to MAIDS by the
TEa and ANDk/k TCR Tg strains. To that end, the
expression of the pathogenic BM5def and helper BM5eco
viruses was determined by validated quantitative RT-PCR
assays (Cook et al., 2003; Green et al., 2004) for the
experiments depicted in Figs. 5–7. First, compared to the
undetectable level of expression of the non-infected groups,
all infected mouse groups demonstrated substantial expres-
sion of BM5def and BM5eco. Second, however, such virus
expression data indicated that viral load in the infected TEa
(Fig. 8A) and ANDk/k (Fig. 8B) TCR Tg strains was not
significantly lower compared to the other infected strains in
which MAIDS was observed. Thus, the resistance of these
two strains to MAIDS was therefore not simply due to a
selective inability of these two TCR Tg strains to become
infected by, or to propagate, the LP-BM5 retroviruses.
Rather, it appeared that these CD4 TCR Tg T cells were
unable to mediate viral pathogenesis.
Concluding remarks
Our studies herein provide strong evidence against a need for
TCR ligation, by complexes of either a specific peptide or a
superantigen (SAg) with class II MHC, for CD4 T cells to fulfilltheir required role in mediating pathogenesis caused by the LP-
BM5 retroviral complex. This conclusion was reached by
careful analysis of a panel of TCR Tg strains of irrelevant
specificities to avoid the possibility of random crossreactive
recognition with a putative LP-BM5 encoded or induced
peptide or SAg. In addition, the presence of contaminating
non-Tg CD4 Tcells, which might have mediated disease as they
are present in significant numbers in many TCR Tg strains, was
countered by either the use of highly purified TCR Tg-positive
CD4 Tcells in adoptive transfer experiments, and/or by crossing
the TCR Tg strains onto a TCRα−/− or RAG-1−/− genetic
background. This backcrossing approach also controlled for any
possible confounding effects if different TCR Tg CD4 T cell
populations exhibited variable survival characteristics after their
adoptive transfer into B6.nude or B6.TCRα−/− recipients. In
addition, by direct analyses, we saw no evidence for such a
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with their ability to mediate MAIDS.
Regardless of the methods utilized, the results were
consistent and clear in showing that the I-Ab restricted OT-II
(anti-OVA) and ANDb/b (anti-PCC) CD4 T cells mediated
MAIDS as assessed by all disease readouts. These data not only
indicate that CD4 T-cell TCR ligation is not a necessity for their
role in disease initiation and progression, but also lead to the
surprising suggestion that the induction of CD154 expression
that is required of the “pathogenic” CD4 T cells must be
occurring in the absence of TCR occupancy and classic
generation on Signal 1. Taken together, these findings thus
imply that there may be novel pathways of induction of CD154
expression by CD4 T cells during the early–mid course of LP-
BM5 infection. Thus, by in vivo mAb blocking experiments
with anti-CD154, we have previously determined that the
requirement for CD154/CD40 interactions persisted from the
time of infection through at least 3 to 4 weeks p.i., but was not
involved at later time points p.i. (Green et al., 1996, 1998). This
disconnect between TCR ligation and the ability of the
pathogenic CD4 T cells to mediate MAIDS, presumably via
CD154 induction (at least in part), was underscored by the
results obtained with OT-II TCR Tg CD4 T cells. These OVA/I-
Ab specific CD4 T cells clearly mediated LP-BM5 induced
MAIDS, but did so only to a partial extent (Figs. 2, and 3).
However, the in vivo introduction of cognate antigen in the
form of OVA injections, which were shown to indeed activate
OT-II CD4 T cells, apparently via Signal 1, etc., did not enhance
the degree of disease (Fig. 4).
An alternative explanation is that CD4 T cell TCR ligation
was accomplished instead by a possible SAg that had specificity
for the Vβ TCR chains of the MAIDS-susceptible OT-II and
ANDb/b (but not the MAIDS-insusceptible TEa, Fig. 5) TCRTg
strains—i.e. Vβ3, 5.1/5.2. However, comparison of the ANDb/b
strain, which is on the B6 background, to the identical Tg TCR
selected instead on the B10.BR (H-2k) background, i. e. the
ANDk/k strain, provided clear evidence that a SAg does not
seem to be involved. Thus, in a set of experiments that
appropriately controlled for both genetic background differ-
ences that could have affected overall MAIDS susceptibility
and a variable percentage of contaminating non-Tg CD4 Tcells,
only the ANDb/b TCR Tg CD4 T cells were able to mediate LP-
BM5 retrovirus induced MAIDS (Figs. 5–7). The inability of
the ANDk/k TCR Tg CD4 T cells, expressing the exact same
TCR, to mediate disease was inconsistent with the possibility
that a SAg existing in this system drives TCR ligation and
generation of Signal 1 to induce CD154 expression. In addition,
our assessment of viral load by quantative RT-PCR (qRT-PCR)
assays for the BM5def and BM5eco viruses indicated that the
MAIDS resistance of the ANDk/k TCR Tg strain was not due to
an inability of the virus to initially infect or spread in this strain,
or in TCRα−/− recipients reconstituted with ANDk/k TCR Tg
CD4 T cells (Fig. 8). Also of interest and related to the nature of
the interaction in MAIDS between CD4 CD154+ T cells and
CD40+ B cells, our ability to induce disease by adoptive transfer
of control polyclonal B10.BR (H-2k) CD4 T cells into B6.
TCRα−/− recipients providing B cells of H-2b origin, isconsistent with a study by Gilmore et al. This study showed
MAIDS development in LP-BM5 infected allochimeric recon-
stituted SCID mice, where the CD4 Tcells and B cells were also
MHC-incompatible in the sense that the T cells were restricted
by an MHC-haplotype not expressed by the B cells (Gilmore et
al., 1993). These studies argue, as do the present data, against
conventional TCR recognition of MHC class II/peptide
complexes on a B-cell “APC” in MAIDS development. In
addition, both this report and several others (Hugin et al., 1991;
Muralidhar et al., 1992; Gilmore et al., 1993; McCarty et al.,
1996; Doyon et al., 1996; Hayashi and Kanagawa, 1999) have
argued against the presence of a SAg in MAIDS, particularly
the one proposed early on as expressed on a terminal B-cell
lymphoma line from a B6 mouse with end-stage MAIDS
(Hugin et al., 1991).
Our results on these two AND TCRTg strains are interesting
to compare to those of Koch et al. (1994) who utilized AND
TCR transgenes crossed onto a (B10.BR×B6) F1, H-2b/k,
background in an attempt to maximize the percent of naïve CD4
T cells on a MAIDS-susceptible genetic background. Thus,
presumably both I-Ab (ANDb/b) and I-Ek (ANDk/k) restricted
TCRTg CD4 T cells were present in these F1 mice. Thus, while
the MAIDS susceptibility of these AND TCR Tg F1 mice
allowed conclusions to be drawn suggesting that naive CD4 T
cells were as efficient as memory CD4 T cells (obtained via
other approaches) in their ability to mediate MAIDS, it was not
possible to distinguish whether the class II MHC restricted H-2b
vs H-2k AND TCRTg CD4 Tcells were the ones mediating LP-
BM5-induced disease. Of note also, the percentage of Tg
(Vβ3Vα11) CD4 T cells in uninfected F1 mice in these
experiments was reported to be 79–88%, leaving open the
possibility that non-Tg CD4 T cells may have participated in
disease pathogenesis.
If TCR ligation is not required to activate CD4 T cells to
express CD154 and otherwise program them so that they can
mediate LP-BM5-induced MAIDS, then how does CD4 T-cell
activation and CD154 expression occur? Although there are
many possibilities, one intriguing mechanism would center on
direct effects of infection by the BM5def virus. Thus, whereas
early reports focused on B cells as the predominant cell type
that is infected and expresses def-gag (Kim et al., 1994;
Klinken et al., 1988), we and others have shown that other
types of cells are also infected, including CD4 T cells as
assessed by qRT-PCR (Cheung et al., 1991; Kim et al., 1994;
K. Green, unpublished data). However, infection of a cell and
expression of viral products does not in itself guarantee that
infection of this cell is central to viral pathogenesis. Rather,
such correlations must be extended to experiments testing the
functional significance of infection/virus expression, and
further studies will be required in which “infectable” versus
“non-infectable” CD4 T cells can be compared in parallel.
Another informative approach may be the comparison of those
TCR Tg CD4 T cells that support LP-BM5 pathogenesis (OT-II
and ANDb/b) versus those that do not (ANDk/k and TEa). Our
preliminary flow cytometric analyses have not revealed any
consistent differences relating to markers (CD44, CD69,
CD45RB, and CD62L) that are together indicative of the
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functional sets of TCR Tg strains. Similarly, although we
were unable to consistently demonstrate expression of cell
surface CD154 by any of the polyclonal or TCR Tg CD4 T
cells when examined immediately ex vivo from infected (or
uninfected) mice, after anti-CD3 mAb stimulation in vitro
(Signal 1), equivalent CD154 expression was detected across
the TCR Tg sources of CD4 T cells that did, or did not, mediate
MAIDS. Thus, there was no evidence for intrinsic differences
in the ability of the different TCR Tg CD4 T cells to be induced
to express CD154. More in-depth analyses are required,
however, which may add further insight into the mechanisms
by which CD4 T cells are stimulated during LP-BM5 infection,
induce CD154 expression, and develop into pathogenic
effector cells that mediate MAIDS.
Materials and methods
Mice
B6, B6.nude, B6.TCRα−/− and B6.RAG-1−/− breeder mice
were purchased from Jackson labs (Bar Harbor, ME) and were
expanded at the Dartmouth Medical School Animal Resource
Center. Breeding pairs for the following TCR Tg strains on
MAIDS genetic susceptible backgrounds with irrelevant
peptide/MHC specificity were obtained (Table 1): OT-II mice
(Dr. Alexander Y. Rudensky, University of Washington School
of Medicine, Seattle, WA), specific for OVA323–339; TEa mice
(Dr. Randolph J. Noelle, Dartmouth Medical School, Hanover,
NH), specific for Eα52–68; and AND (H-2
b/b) and AND (H-2k/k)
mice (Dr. Susan Swain, Trudeau Institute, Saranac Lake, NY),
specific for PCC81–104. These TCR Tg strains were used as a
source of TCRTg CD4 Tcells, or were crossed onto either a B6.
TCRα−/− or a B6.RAG-1−/− background.
LP-BM5 virus inoculations
LP-BM5 virus was prepared as previously described (Klinken
et al., 1988). Briefly, G6 cells, cloned from SC-1 fibroblasts
infectedwith the LP-BM5 virus mixture, and originally provided
by Janet Hartley and Herbert Morse (NIH/NIAID, Bethesda,
MD), were cocultured with uninfected SC-1 cells, and viral
supernates were obtained. Mice were infected i.p. with 1×105
ecotropic PFU virus stock unless otherwise indicated.
Purification of CD19 B cells or CD4 T cells from B6 or TCR Tg
donors
CD4 T cells or CD19 B cells from normal w.t. B6 donors
were purified with Miltenyi beads, using either anti-CD4 or
-CD19 beads following the manufacturer's protocol, with cell
subset purity ≥98%, as detected by flow cytometric analysis.
Purified CD4 T cells (1×107, unless otherwise indicated) were
adoptively transferred (i.v.) into either B6.nude or B6.TCRα−/−
recipients; or CD4 T cells (2×107) and CD19 B cells (1×108)
were adoptively transferred into either the B6.RAG-1−/− strain,
or B6.RAG-1−/− littermate offspring from crosses of B6.RAG-1−/− mice with either TEa or ANDb/b TCR Tg mice. TCR Tg+
CD4 T cells, derived from TCR Tg strains (Table 1), were
purified and used in similar reconstitution experiments. A
portion of the recipients was infected with LP-BM5 48 h after
adoptive transfer, and the remaining mice receiving adoptive
cell transfer served as uninfected controls.
Purification of OT-II TCR Tg CD4 T cells
Splenocytes from OT-II TCR Tg donors were labeled with
FITC anti-TCRVβ5.1, 5.2, followed by anti-FITC beads for
Miltenyi separation. Purified OT-II TCR Tg CD4 T cells were
stained by use of FITC anti-TCRVβ5.1, 5.2 and PE anti-CD4,
with analysis by FACSCalibur (BD Bioscience) to check the
purity (≥98%). Appropriate FITC and PE conjugated Ig
isotypes of irrelevant specificity were used as controls.
Purification of CD4 T cells from ANDb/b and ANDk/k TCR Tg
donors
Splenocytes from ANDb/b and ANDk/k TCR Tg donors were
labeled with FITC anti-TCRVβ3, followed by anti-FITC beads
for Miltenyi separation. Purified (≥98%) TCRTg+ CD4 Tcells,
or w.t. polyclonal B6 CD4 T cells purified as positive controls,
were adoptively transferred into B6.TCRα−/− recipients.
Crossing various TCR Tg strains onto either a B6.TCRα−/− or
a B6.RAG-1−/− background
The OT-II TCR Tg strain onto a B6.TCRα−/− background
OT-II TCR Tg male and B6.TCRα−/− female mice were
bred, and the male Tg+ F1 offspring were bred back to B6.
TCRα−/− females. The backcrossed offspring were screened
by flow cytometry for Tg positivity via use of FITC anti-
TCRVβ5.1,5.2; PE anti-CD4; and appropriate FITC and PE
conjugated Ig isotypes of irrelevant specificity; and for
TCRα−/− status by PCR (Mombaerts et al., 1992). To study
the effect of ovalbumin (OVA) immunization, these OT-II
TCR Tg+ TCRα−/− experimental mice were injected i.p. with
OVA during the course of LP-BM5 infection: 50/ug of OVA in
CFA per mouse at day −1 p.i., and either 50/ug of OVA in
IFA at days 10 and 20 p.i., or at days 12, 24 and 36 p.i.
Peripheral blood lymphocyte samples, obtained at days 2, 5,
14, 25 and 39 p.i., were analyzed by flow cytometry for
markers of CD4 T cell activation: CD62L and CD69; and
functional assessment of their ability to proliferate in response
to OVA stimulation.
The ANDb/b TCR Tg strain onto a B6.RAG-1−/−
background
ANDb/b TCR Tg mice were crossed with B6.RAG-1−/−
mice, and F1 Tg+ offspring were bred back to B6.RAG-1−/−
mice, with the resulting offspring screened by flow cytometry
using the following mAbs: FITC anti-TCRVβ3, PE anti-CD19,
APC anti-CD4 and appropriate FITC, PE, and APC conjugated
Ig isotypes controls. Of the offspring approximately 1/4 were
ANDb/b TCR Tg+ RAG-1−/− (Tg+, CD4+, CD19−) mice; these
mice were recipients of adoptive transfer of CD19 B cells from
B6 donors as the experimental group. Another 1/4 of the
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CD19−) mice; these mice were recipients of adoptive transfer of
CD19 B cells plus polyclonal CD4 T cells from w.t. B6 donors
as a positive control group.
The TEa TCR Tg strain onto a B6.RAG-1−/− background
TEa TCR Tg mice, already crossed onto a B6.RAG-1−/−
background, were bred with B6.RAG-1−/− mice and the
progeny screened for Tg status and RAG-1−/− background
with flow cytometry by use of FITC anti-TCRVβ6, PE anti-
CD19, APC anti-CD4 mAbs, and appropriate FITC, PE, and
APC conjugated Ig isotype of controls. Of the offspring about
1/2 were TEa TCR Tg+ RAG-1−/− (Tg+, CD4+, CD19−) mice;
these mice were recipients of adoptive transfer of CD19 B cells
from B6 donors as the experimental group. The other ∼ 1/2 of
the offspring were TEa TCR Tg− RAG-1−/− (Tg−, CD4−,
CD19−) mice; these mice were recipients of adoptive transfer
of CD19 B cells plus CD4 T cells from B6 donors as a positive
control group.
ELISA determinations of serum Ig
For measuring hyper-Ig, goat anti-mouse IgM and IgG2a
antibody (Southern Biotechnology, Birmingham, AL), was
coated in 96-well enzyme-linked immunosorbent assay
(ELISA)-grade plates (Becton Dickinson, Oxford, CA) as
previously published (Li and Green, 2006). Sera, from control
uninfected mice, or obtained at various times post LP-BM5
infection, including at the final termination time point, were
then plated and followed with alkaline phosphatase-labeled goat
anti-mouse Ig (Southern Biotechnology). After incubation,
addition of p-nitrophenyl phosphate as substrate (Sigma)
provided a colorimetric change, which was then quantitated at
405 nm by an ELISA reader (Dynatech Laboratories, South
Hampton, UK).
Spleen cell responses to mitogen
As previously detailed (Li and Green, 2006), spleen cells
(4×105/per well) were plated into 96-well plates with a final
concentration of 10 μg/ml LPS. After 72 h, wells were pulsed
with 1 μCi of [3H] thymidine (Dupont NEN, Boston, MA) and
harvested 6 h later onto Unifilter 96 well GF/C plates for
assessment of thymidine incorporation by scintillation counting
(Packard MicroSant NXT Counter).
RNA isolation and real-time quantitative RT-PCR
Viral load was determined for BM5def and BM5eco as
previously described (Cook et al., 2003; Green et al., 2004).
Briefly, total RNA was isolated from spleen tissue using Tri-
Reagent (Molecular Research Center, Cincinnati, OH) and
treated with DNA-free kit (Ambion, Austin, TX). Following
reverse transcriptase amplification of cDNA (Bio-Rad iScript
cDNA Synthesis kit), quantitative RT-PCR was performed
using iQ SYBR Green Supermix and iCycler software (Bio-
Rad, Hercules, CA).Statistical analyses
Multiple group comparisons have been conducted to test
possible group differences using one-way ANOVA and
SPSS software. To control for type I error due to multiple
tests, the BONFERRONI correction has been applied. The
results were significant (⁎, P<0.05) or not significant (NS,
P≥0.05).
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